- Home
- MBBC vs CALC Comparison
MBBC vs CALC Comparison
Compare MBBC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- CALC
- Stock Information
- Founded
- MBBC 1902
- CALC 2011
- Country
- MBBC United States
- CALC United States
- Employees
- MBBC N/A
- CALC N/A
- Industry
- MBBC Banks
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- CALC Health Care
- Exchange
- MBBC Nasdaq
- CALC Nasdaq
- Market Cap
- MBBC 22.1M
- CALC 20.9M
- IPO Year
- MBBC N/A
- CALC N/A
- Fundamental
- Price
- MBBC $10.05
- CALC $2.00
- Analyst Decision
- MBBC
- CALC Strong Buy
- Analyst Count
- MBBC 0
- CALC 3
- Target Price
- MBBC N/A
- CALC $16.33
- AVG Volume (30 Days)
- MBBC 13.3K
- CALC 27.5K
- Earning Date
- MBBC 05-12-2025
- CALC 05-20-2025
- Dividend Yield
- MBBC N/A
- CALC N/A
- EPS Growth
- MBBC N/A
- CALC N/A
- EPS
- MBBC N/A
- CALC N/A
- Revenue
- MBBC $6,554,694.00
- CALC N/A
- Revenue This Year
- MBBC N/A
- CALC N/A
- Revenue Next Year
- MBBC N/A
- CALC N/A
- P/E Ratio
- MBBC N/A
- CALC N/A
- Revenue Growth
- MBBC N/A
- CALC N/A
- 52 Week Low
- MBBC $5.83
- CALC $1.43
- 52 Week High
- MBBC $12.00
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- CALC 63.80
- Support Level
- MBBC N/A
- CALC $1.94
- Resistance Level
- MBBC N/A
- CALC $2.15
- Average True Range (ATR)
- MBBC 0.00
- CALC 0.14
- MACD
- MBBC 0.00
- CALC 0.08
- Stochastic Oscillator
- MBBC 0.00
- CALC 79.06
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.